Nicholas C Turner (Nicholas Turner)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 24

Top Topics

Estrogen Receptor

Circulating Tumor

Locally Advanced

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

NPJ breast cancer

Nature communications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andres Cervantes, Valentina Gambardella, Erika Paige Hamilton, Antoine Italiano, Kevin M Kalinsky, Ian E Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L Schutzman, Dejan Juric
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Henrique Barrios, Joyce O'Shaughnessy, Steven Jay Isakoff, Shigehira Saji, Rui Gilberto Ferreira, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J Wongchenko, Sarah-Jayne Reilly, Nicholas C Turner
Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Belinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind J Cutts, Heena Shah, Laura Moretti, Lucy Suzanne Kilburn, Hannah Johnson, Iain R J Macpherson, Alistair Ring, Judith M Bliss, Yingwei Hou, Weiyi Toy, John A Katzenellenbogen, Sarat Chandarlapaty, Nicholas C Turner
ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1 mutant breast cancer. Cancer discovery (2023)
Curigliano Giuseppe, Rebecca Dent, Antonio Llombart-Cussac, Mark D Pegram, Lajos Pusztai, Nicholas C Turner, Giuseppe Viale
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer 9 (1) (2023)
Angel L Guerrero-Zotano, Stefania Belli, Christoph C Zielinski, Juan Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz Borrego, Eva Ciruelos Gil, Javier Pascual, Montserrat Muñoz, Begoña Bermejo, Mireia Margelí, Antonio Antón-Torres, Laura Murillo, Bella Nisenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalía Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas C Turner, Miguel Martin
CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Komal L Jhaveri, Meritxell Bellet-Ezquerra, Nicholas C Turner, Sherene Loi, Aditya Bardia, Valentina Boni, Joo Hyuk Sohn, Tomas G Neilan, Rafael Villanueva-Vázquez, Peter Kabos, Laura García Estévez, Elena Lopez-Miranda, José Alejandro Pérez-Fidalgo, Jose Manuel Perez-Garcia, Jiajie Yu, Jill Fredrickson, Heather M Moore, Ching-Wei Chang, John W Bond, Jennifer Eng-Wong, Mary R Gates, Elgene Lim
Phase Ia/b Study of Giredestrant ±Palbociclib and ±Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Javier Pascual, Juan Miguel Gil-Gil, Paula Z Proszek, Christoph C Zielinski, Alistair Reay, Manuel Ruiz Borrego, Rosalind J Cutts, Eva Ciruelos Gil, Andrew Feber, Montserrat Muñoz, Claire Swift, Begoña Bermejo, Jesus Herranz, Mireia Margelí, Antonio Antón-Torres, Zsuzsanna Kahán, Tibor Csőszi, Yuan Liu, Daniel Fernandez-Garcia, Isaac Garcia-Murillas, Michael Hubank, Nicholas C Turner, Miguel Martin
Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Amanda Fitzpatrick, Marjan Iravani, Adam Mills, David Vicente, Thanussuyah Alaguthurai, Ioannis Roxanis, Nicholas C Turner, Syed Haider, Andrew N J Tutt, Clare M Isacke
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. Nature communications 14 (1) (2023)
Nicholas C Turner, A Douglas Laird, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A Mina, Judith Balmaña, Peter Andreas Fasching, Sara Alsterlind Hurvitz, Julia F Hopkins, Lee A Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M Wardley, Mark E Robson
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ breast cancer 9 (1) (2023)
Maria Coakley, Guillermo Villacampa, Prithika Sritharan, Claire Swift, Kathryn Dunne, Lucy Suzanne Kilburn, Katie Goddard, Christodoulos Pipinikas, Patricia Rojas, Warren Emmett, Peter S Hall, Catherine Harper-Wynne, Tamas Hickish, Iain R J Macpherson, Alicia F C Okines, Andrew M Wardley, Duncan A Wheatley, Simon H Waters, Carlo Palmieri, Matthew C Winter, Rosalind J Cutts, Isaac Garcia-Murillas, Judith M Bliss, Nicholas C Turner
Comparison of circulating tumor DNA assays for Molecular Residual Disease detection in early-stage triple negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Laura Morrison, Sibylle Loibl, Nicholas C Turner
The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nature reviews. Clinical oncology (2023)
Curigliano Giuseppe, Rebecca Dent, Antonio Llombart-Cussac, Mark D Pegram, Lajos Pusztai, Nicholas C Turner, Giuseppe Viale
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer 9 (1) (2023)
Peter Schmid, Nicholas C Turner, Carlos Henrique Barrios, Steven Jay Isakoff, Sung-Bae Kim, Marie-Paule Sablin, Shigehira Saji, Peter Savas, Gregory A Vidal, Mafalda Oliveira, Joyce O'Shaughnessy, Antoine Italiano, Enrique Espinosa, Valentina Boni, Shane White, Beatriz Rojas, Rui Gilberto Ferreira, Yee Soo Chae, Igor Bondarenko, Jieun Lee, Cesar Torres Mattos, Jorge Luis Martinez Rodriguez, Lisa H Lam, Surai Jones, Sarah-Jayne Reilly, Xiayu Huang, Kalpit Shah, Rebecca A Dent
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Niamh Cunningham, Nicholas C Turner
Liquid Biopsies in Breast Milk for the Early Detection of Breast Cancer. Cancer discovery 13 (10) (2023)
Arielle J Medford, Beverly Moy, Laura M Spring, Sara Alsterlind Hurvitz, Nicholas C Turner, Aditya Bardia
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Michael Gnant, Nicholas C Turner, Cristina Hernando
Managing a Long and Winding Road: Estrogen Receptor-Positive Breast Cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 43 (2023)
Curigliano Giuseppe, Rebecca Dent, Antonio Llombart-Cussac, Mark D Pegram, Lajos Pusztai, Nicholas C Turner, Giuseppe Viale
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer 9 (1) (2023)
Alistair Ring, Lucy Suzanne Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr, Andrew M Wardley, Bora Gurel, Iain R J Macpherson, Ruth Riisnaes, Richard D Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C Winter, Kathryn Dunne, Ellen R Copson, Tamas Hickish, Russell Burcombe, Kat Randle, Violeta Serra, Alba Llop-Guevara, Judith M Bliss, Nicholas C Turner
Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Nicholas C Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen K L Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X Ma, Erica L Mayer, Jang-Yeon Park, Steven Fox, Xiaochun Liu, Sasha McClain, Francois-Clement Bidard
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment. Future oncology (London, England) (2023)
Norah L Henry, Mark R Somerfield, Zoneddy Dayao, Anthony D Elias, Kevin Kalinsky, Lisa Meier McShane, Beverly Moy, Ben Ho Park, Kelly M Shanahan, Priyanka Sharma, Rebecca Shatsky, Erica M Stringer-Reasor, Melinda Telli, Nicholas C Turner, Angela M DeMichele
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (27) (2022)
Zhou Zhu, Nicholas C Turner, Sherene Loi, Fabrice André, Miguel Martin, Véronique Diéras, Karen A Gelmon, Nadia Harbeck, Cathy Zhang, Joan Q Cao, Zhengming Yan, Dongrui R Lu, Ping Wei, Todd L VanArsdale, Paul A Rejto, Xin Huang, Hope S Rugo, Sibylle Loibl, Massimo Cristofanilli, Richard S Finn, Yuan Liu
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ precision oncology 6 (1) (2022)
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Nuria Lopez-Bigas, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández-Losa, Faye Su, Kui Lin, Robert B Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C Turner, Aleix Prat, Paolo G Nuciforo, Rodrigo Dienstmann, Chandra S Verma, Núria López-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nature communications 13 (1) (2022)
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Nuria Lopez-Bigas, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández-Losa, Faye Su, Kui Lin, Robert B Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C Turner, Aleix Prat, Paolo G Nuciforo, Rodrigo Dienstmann, Chandra S Verma, Núria López-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nature communications 13 (1) (2022)
Nicholas C Turner, Rebecca A Dent, Joyce O'Shaughnessy, Sung-Bae Kim, Steven J Isakoff, Carlos Barrios, Shigehira Saji, Igor Bondarenko, Zbigniew Nowecki, Qinshu Lian, Sarah-Jayne Reilly, Heather Hinton, Matthew J Wongchenko, Bruno Kovic, Aruna Mani, Mafalda Oliveira
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast cancer research and treatment (2021)